PFE Pfizer

Pfizer Declares Third-Quarter 2021 Dividend

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on Twitter at and and like us on Facebook at .

EN
24/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports by Pfizer

PFE PFIZER (Health Care)

Moody's assigns A2 to Pfizer's sr. notes; stable outlook

Rating Action: Moody's assigns A2 to Pfizer's sr. notes; stable outlook. Global Credit Research- 16 Aug 2021. New York, August 16, 2021-- Moody's Investors Service assigned an A2 rating to the new senior unsecured notes being issued by Pfizer Inc..

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
PFE PFIZER (Health Care)

COVID-19 - “Houston, We Have a Problem” (7 pgs)

An Israeli study published on Thursday showed that vaccine efficacy waned significantly against the Delta variant after ~6 months with efficacy down to just 16% for those vaccinated in January. Furthermore, hospitalisation rates also seemed to be higher in those vaccinated in January. Israel vaccinated its population the fastest so is best placed to conduct studies on vaccine durability. We assess the consequences of such a rapid loss of protection against the Delta variant which is becoming the...

PFE PFIZER (Health Care)

PFIZER increases its risk exposure and slightly lowers to Neutral

PFIZER (US), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date July 6, 2021, the closing price was USD 39.29 and its exp...

 PRESS RELEASE
PFE PFIZER (Health Care)

Pfizer Declares Third-Quarter 2021 Dividend

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company’s common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the ...

 PRESS RELEASE
PFE PFIZER (Health Care)

First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combinat...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC). The first patient was dosed at a site in Glendale, California. “Th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch